Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients

Gabriel Perlemuter,Patrice Cacoub,Dominique Valla,Dominique Guyader,Barbara Saba,Cécile Batailler,Kevin P. Moore

Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients

2016

Gabriel Perlemuter
Patrice Cacoub
Dominique Valla
Dominique Guyader
Barbara Saba
Cécile Batailler
Kevin P. Moore

Background Antidepressant-induced liver injury is a major concern and a liver monitoring scheme has been recommended by the European Medicines Agency for agomelatine.

Keywords:

Duloxetine
Psychiatry
Agomelatine
Generalized anxiety disorder
Fatty liver
Major depressive disorder
Placebo-controlled study
Liver injury
Liver function tests
Medicine
Pharmacotherapy
Pharmacology
Retrospective cohort study

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations